AB-FUBINACA: Difference between revisions

>Unity
Standardized style and content
>Unity
Removed unclear wording
Line 13: Line 13:


==Pharmacology==
==Pharmacology==
Although this substance has not been formally studied, from analysis of the structure, it is presumed that AB-FUBINACA has a similar binding profile to that of other [[cannabinoids]] and matches many of the in vivo properties of [[Δ9-THC]]. As with the compounds within [[cannabis]], AB-FUBINACA exhibits its range of effects via full [[agonism]] of both the [[Cannabinoid#Cannabinoid_receptor_type_1|CB1]] and [[Cannabinoid#Cannabinoid_receptor_type_2|CB2]] [[cannabinoid]] [[receptors]], with some selectivity for CB2. However, the role of these interactions and how they result in the cannabinoid high experience continues to remain elusive.
Although this substance has not been formally studied, from analysis of the structure, it is presumed that AB-FUBINACA has a similar binding profile to that of other [[cannabinoids]] and matches many of the in vivo properties of [[Δ9-THC]]. AB-FUBINACA exhibits its range of effects via full [[agonism]] of both the [[Cannabinoid#Cannabinoid_receptor_type_1|CB1]] and [[Cannabinoid#Cannabinoid_receptor_type_2|CB2]] [[cannabinoid]] [[receptors]], with some selectivity for CB2. However, the role of these interactions and how they result in the cannabinoid high experience continues to remain elusive.


==Subjective effects==
==Subjective effects==